ASCO GI 2027: 5 GI Cancer Abstracts That Could Move Stocks
ASCO GI 2027 is the first oncology catalyst window of the year. Screen these five GI-cancer datasets on January 19, the day full abstracts drop. Here is why.
September 29, 2026Biotech News — analysis
ASCO GU 2027: 5 Genitourinary Abstracts That Move Stocks
ASCO GU 2027 runs Feb 11-13 in San Francisco and abstract titles drop early January. Five GU names to screen, and the two small caps that re-rate 30%.
September 28, 2026Camurus Oclaiz Dec 18 PDUFA: 85% Approval Odds
Oclaiz's two CMC-only CRLs make the Dec 18 PDUFA a near-certain approval, but Vertex's $10B Palsonify bet means Camurus wins an injection war in a pill market.
September 28, 2026SABCS 2026: 5 Breast Cancer Abstracts That Move Stocks
Every trader screens ASCO. The edge is SABCS, the Q4 breast meeting no one previews. Five ranked abstracts and the two names that actually re-rate 30%.
September 28, 2026ACR 2026: 5 Autoimmune CAR-T Abstracts That Move Stocks
The autoimmune CAR-T trade fires at abstract release in October, not the November 6-11 meeting. Five biotech names where one dataset re-rates shares 15-30%.
September 27, 2026Best Biotech Stocks 2027: 7 Multi-Shot Platforms, 2 Avoids
The 2026 catalysts already resolved. 2027 rewards companies with a second shot on goal. Seven multi-shot platforms ranked by risk-reward, plus two avoids.
September 27, 2026CTAD 2026: 5 Alzheimer's Abstracts That Could Move Stocks
The CTAD trade fires at abstract release in late October, not the November 16-19 meeting. Five biotech names where one dataset re-rates shares 15-30%.
September 27, 2026JPM 2027: 6 Names That Move on Deals, Not Data
ASCO moves oncology, ASH moves hematology, JPM moves deals. Six names with a 2027 catalyst and a cash runway or buyout question, ranked by deal-flow potential.
September 27, 2026SITC 2026: 5 Immuno-Oncology Abstracts That Move Stocks
The SITC trade fires at abstract release November 3, not the November 4-8 meeting in Phoenix. Five biotech names where one dataset re-rates shares 15-30%.
September 27, 2026ASH 2026: 5 Hematology Abstracts That Could Move Stocks
The ASH 2026 trade fires at abstract release on November 4, not at the December 12-15 meeting. Five names where one dataset re-rates shares 15-30%. Here is why.
September 26, 20262027 FDA Calendar: 5 PDUFAs Ranked
2027's first half has 9 confirmed PDUFA dates. Five are investable binary events. Two are ghosts: one approved, one with no US ticker. Here is the playbook.
September 26, 2026Q3 2026 Biotech Earnings: 8 Names to Watch
Ignore GAAP EPS. Q3 earnings matter only when they carry a pipeline, guidance, or runway signal. Here are the 8 names and the one number to watch on each.
September 26, 2026RHHBY Giredestrant SERD: Two PDUFAs in ER+ Breast Cancer
Roche's oral SERD, giredestrant, won adjuvant lidERA (HR 0.70) and evERA in ESR1-mutant disease (HR 0.38), but the franchise matters more than the stock.
September 26, 2026RHHBY Tecentriq: 50% Recurrence Cut in dMMR Colon Cancer
ATOMIC cut recurrence or death risk by 50% in stage III dMMR colon cancer (HR 0.50), but for Roche's CHF 262 billion ship the Oct 9 PDUFA is immaterial.
September 26, 2026ACAD Remlifanserin: 0.26 Effect Size, Alzheimer's Psychosis
Acadia missed RADIANT's primary endpoint (p=0.0603) but is advancing remlifanserin to Phase 3 in ADP anyway. A 0.26 effect size is what decides everything.
September 25, 2026AMGN Dazodalibep: Phase 3 Sjögren's Win, No Magnitude
Dazodalibep hit its Phase 3 ESSDAI endpoint in Sjögren's, the first Horizon asset to win. But no magnitude disclosed and ianalumab ahead, the stock won't move.
September 25, 2026INSM ARIKAYCE: Full Approval Near-Certain, $26B Priced In
ARIKAYCE's ENCORE data makes full approval highly likely. The real question is whether frontline MAC expansion moves revenue, and the stock already says yes.
September 25, 2026JNJ Caplyta Mania Win: 4.8-Point YMRS, Bipolar Franchise
Caplyta's 4.8-point YMRS mania win turns J&J's $14.6B Intra-Cellular bet into a full-spectrum bipolar franchise, but the $643B stock won't move for investors.
September 25, 2026RHHBY Enicepatide: 62% Normoglycemia Tops GLP-1
Enicepatide's 62% normoglycemia in Phase 2 T2D beats tirzepatide and retatrutide on glucose, but Roche is late, Phase 3 is years out, and RHHBY won't move.
September 25, 2026SYRE SPY003: Three-for-Three IBD Data, $7.7B Priced In
Spyre hit proof-of-concept on all three IBD mechanisms. Monotherapy data is in-line, not best-in-class; the real bet is the 2027 Part B combination readout.
September 25, 2026Ionis' Sefaxersen: A Phase 3 Win With the Number Missing
Ionis and Roche's sefaxersen met its IgAN Phase 3 endpoint, but Roche hid the proteinuria magnitude. Here's what that silence means for a $7.3B stock.
September 24, 2026Merck Remigromig: Non-Inferior in DME, Higher PDR Rates
Remigromig cleared BRUNELLO on non-inferiority to ranibizumab, but higher PDR and vitreous hemorrhage cloud AAO readout. Merck's $3B EyeBio bet is unsettled.
September 24, 2026VKTX VK2735: 90% Maintenance, $4.9B Market Cap
VK2735 kept 90% of weight loss on monthly dosing and hit 22% placebo-adjusted loss. Viking priced a $500M raise into the rally. Buy the pullback, size it small.
September 24, 2026VRTX Inaxaplin Cuts Proteinuria 42.7% in AMKD
Inaxaplin cut proteinuria 42.7% in AMKD, but the type 2 diabetes cohort missed significance. The 466-patient AMPLITUDE interim in early 2027 is the real test.
September 24, 2026AZN Tozorakimab: 34% COPD Exacerbation Cut, $5B Peak
Sanofi killed its IL-33 drug; AstraZeneca's tozorakimab showed a 34% COPD exacerbation cut across every patient group. The $5B peak-sales call is now credible.
September 10, 2026ROIV Mosliciguat: 56% PVR Readout in PH-ILD Phase 2
Roivant's inhaled mosliciguat posted the largest PVR reduction ever seen in a controlled PH trial. The Phase 3 PHrontier study will decide if it unseats Tyvaso.
September 10, 2026ACET Prula-cel: $88M CD20 CAR-T Lupus Primer
Adicet's allogeneic CD20 CAR-T reads out in 22 lupus patients this month. At $88M, a clean 12-month print re-rates the stock; a safety stumble halves it.
September 4, 2026NVO Mim8 43 Business Days Past PDUFA: A Roche Story
Mim8 is 43 business days past its July 29 PDUFA. The delay reads as labeling negotiation, not a CRL, and the real trade is Roche's Hemlibra franchise.
September 4, 2026The 2026 Approval Class: First-Quarter Launch Report Card
Six drugs won FDA approval in July-August 2026. Only two moved the stock. Here is the launch report card, ranked from highest conviction to rounding error.
September 3, 2026ESMO 2026: 5 Biotech Abstracts That Could Move Stocks
ESMO 2026 runs Sept 17-21 in Madrid and abstracts drop mid-September. Five mid-cap names where one dataset could re-rate shares 15-30% before the presentation.
September 3, 2026GU Oncology: Pluvicto Doubled Prostate, 3 Catalysts to 2027
GU oncology is the one cancer subsector where approvals expand the addressable population, not reshuffle share. Here is how to rank the next three catalysts.
September 3, 2026GSK Pays $110M for HUTCHMED's HMPL-A830 KRAS-EGFR ATTC
GSK paid $110M upfront for HUTCHMED's preclinical KRAS-EGFR ATTC. The $1.3B headline is milestone math. For HUTCHMED it's validation; for GSK it's immaterial.
September 3, 2026Migraine's $5B Market and the PACAP Names No One Is Pricing
CGRP drugs are a $5 billion market consolidating around AbbVie's oral franchise. The next wave, PACAP targeting, is where the binary upside lives for investors.
September 3, 2026Q4 Biotech Playbook: Buy the Washout, Front-Run BBIO, SVRA
Everyone sells biotech into December. That is when to buy. Four tax-loss washout names, nine PDUFA dates ranked, and the sizing rules that keep you solvent.
September 3, 2026BioMarin's 20% Yuviwel Royalty Is a Bridge, Not a Win
BioMarin collects 20% on Ascendis weekly achondroplasia drug through 2030. That is roughly $720M by 2030, but it recovers only 20 cents per lost Voxzogo dollar.
September 2, 2026 · Rare Disease · $BMRNRare Endocrine Catalysts: Three 2026-2027 Drug Wars
TED, hypoparathyroidism, and achondroplasia each have a live 2026-2027 catalyst. BridgeBio owns two of the three, and its $15B price does not reflect it.
September 2, 2026TLX Pre-Biopsy NDA Opens 3x Bigger PSMA-PET Market
Telix completed BiPASS enrollment and aligned with the FDA on a pre-biopsy NDA. If approved, the market triples while TLX trades at a discount to Lantheus.
September 2, 2026ALMS Envudeucitinib: 24-Point IFNGS-High Lupus Split
Envudeucitinib missed BICLA in the overall LUMUS population but posted a 24-point delta in IFNGS-high lupus. The psoriasis NDA in Q4 2026 is unaffected.
September 1, 2026Autoimmune CAR-T: Three Deaths, Which Pure Plays Survive
Novartis paused eight rap-cel trials after three deaths and BMS followed. The field repriced overnight; here is which pure plays survive the higher bar.
September 1, 2026Biotech Activism: CAPR Board Fight and $4.09 Cash Per Share
Industrial activists want margin. Biotech activists want pipeline culls and M&A. How to spot the setup, trade the 13D, and why CAPR's fight can't fix a PDUFA.
September 1, 2026MS BTK Race Over: Fenebrutinib Won, Tolebrutinib CRL'd
Everyone is waiting for the MS BTK race to resolve. It already did. Fenebrutinib swept three Phase 3 trials, Sanofi got rejected, and the moat held firm.
September 1, 2026PCVX VAX-31: $10B Pneumococcal Binary, Q4 Readout
A $8.9 billion pre-revenue company is betting on a Q4 head-to-head against Merck's Capvaxive. The trial, the market math, and the risk for PCVX investors.
September 1, 2026AI Drug Discovery: Relay's $4.1B Is the Only Phase 3 Name
Schrödinger, Recursion, Absci, and Relay all claim to be AI drug companies. Only one has a registrational Phase 3 asset. Here is the ranking by catalyst.
August 31, 2026GLP-1 2.0: Amylin and Orals Ranked After Lilly's $1.05T Run
The injectable GLP-1 duopoly is worth $1.26 trillion. The second wave, amylin analogs and oral GLP-1s, is where the multiples are sane. Ranked by catalyst.
August 31, 2026Neuromuscular Ranked: 6 Binary Catalysts From DMD to FSHD
DMD, SMA, LGMD, and FSHD share one thesis: orphan pricing and a dense 2026 catalyst stack. Here are the six names ranked by nearest tradeable binary event.
August 31, 2026Parkinson's 2026: ABBV Tavapadon vs PRTA Prasinezumab
One million US patients, zero disease-modifying drugs. Tavapadon is now approved, prasinezumab is the last modifier standing, and the graveyard is full.
August 31, 2026Protein Degraders: 2 FDA Approvals, 5 Pure-Plays Ranked
Zenbexus and VEPPANU made degraders a proven class in 2026. The five pure-plays are ranked by catalyst, with Kymera priced and Nurix the best risk-reward.
August 31, 2026Vaccine Stocks Ranked: mRNA Won Flu, PCVX Next Binary
The market wrote off vaccines after COVID. Vaxcyte's Q4 PCV readout, Moderna's cancer vaccine, and the mRNA vs protein war, ranked by nearest catalyst.
August 31, 2026GLP-1s Erase 7.4% Muscle: The $7B Anti-Myostatin Fix Ranked
GLP-1 weight loss is 25-40% lean mass. Scholar Rock's apitegromab (Sept 30 PDUFA) leads the anti-myostatin fix while Lilly retreats on bimagrumab. Ranked.
August 30, 2026Bone Health Stocks: 5 Names in Biotech's $20B Market
Osteoporosis, rare bone disease, and the elusive DMOAD converge in one under-covered market. Five bone-health stocks ranked by market cap and catalyst timing.
August 30, 2026Orexin Agonists: $10B Wake-Up Call. Takeda Won Round One.
Takeda's Orzeyful (oveporexton) won first FDA approval Aug 5. Alkermes, Centessa, and Axsome now race for narcolepsy type 2, hypersomnia, and cataplexy. Ranked.
August 30, 2026PRAX Relutrigine: $7.8B SCN2A/SCN8A Epilepsy Primer
Praxis trades at $7.8B with relutrigine's PDUFA pushed to Dec 27. EMBOLD showed a 46% placebo-adjusted seizure cut, but the extension is a yellow flag.
August 30, 2026Psychedelics Stocks: 6 Names Ranked After Lilly's $2.8B Bet
After the Lykos CRL, Lilly's $2.8B AtaiBeckley deal revived psychedelics. Six names ranked from Compass Pathways to MindMed by market cap and catalyst.
August 30, 2026SRRK Apitegromab: $7.04B First SMA Add-On, Sept 30 PDUFA
SRRK trades at $7.04B with a Sept 30 PDUFA. SAPPHIRE hit its combined endpoint (p=0.019) but the 20 mg/kg dose missed. Approval is likely; the price is not.
August 30, 2026BBIO Attruby: $222M Q2, $15B Cap, 3 Launches to Justify It
Attruby grew 211% YoY to $222M in Q2, but a $15B valuation needs BBP-418, encaleret, and infigratinib to all hit. The launch is real; the multiple is not free.
August 29, 2026BMY Zenbexus: CELMoD Bet Works, $136B Stock Won't Move
BMS's Zenbexus is the first CELMoD and the first myeloma drug approved on MRD negativity (41% vs 21%, p<0.0001). The class is real; the stock move is not.
August 29, 2026Non-Opioid Pain 2026: Vertex Anchors, Latigo Is the Trade
The race to replace opioids has one approved mechanism (NaV1.8), two mega-caps, and a $1.5B pure play with better-than-opioid data. Here is the ranking.
August 29, 2026REPL Tudriqev: $450K Melanoma Launch at $1.46B Cap
Tudriqev's $450K launch is funded by a $150M raise, but the first oncolytic virus for melanoma must beat Amtagvi and T-VEC's ghost for 10K refractory patients.
August 29, 2026SRPT Elevidys: $945M Cash, 4 Approved Drugs, $2.2B Cap
Three Elevidys deaths cut Sarepta from $120 to $16. At $21 and a $2.2B market cap, the DMD franchise trades at 1x revenue. The contrarian trade, honestly.
August 29, 2026VERA Trutakna: ORIGIN 3 eGFR Readout Decides Approval
Trutakna's accelerated approval hinges on ORIGIN 3's eGFR readout, due within weeks. A flat Phase 2b slope says convert; the proteinuria gap says be careful.
August 29, 2026Biotech Cycle: XBI Up 38% YTD, 3% From Record High
The funding winter ended, the IPO window is open, and M&A is at a record pace. But the 10-year yield is 4.66%. Here is where the cycle is and what to do.
August 28, 2026CRSP CTX310: One Year of Durability for In Vivo Editing
CTX310 held a 79% ANGPTL3 cut and a 53% LDL cut for a full year after one infusion. That answers the field's biggest question. Here's the trade for CRSP.
August 28, 2026RHHBY DUPAC Deal: $1B ADC Payloads, Zero Stock Impact
Genentech paid $45M upfront for DualityBio's DUPAC platform to beat ADC payload resistance. It's a 0.3% blip on Roche's $354B cap. The trade is elsewhere.
August 28, 2026RVMD Rasonque: $47B Cap Before Its First Sales Print
Rasonque's $39,800 monthly price is 2x Keytruda's, and RVMD now trades at a $47B cap before a single sales print. A historic launch, an unproven franchise.
August 28, 2026LTGO Latigo: Nav1.8 Pure Play Beats Hydrocodone
Vertex proved Nav1.8 works, but Latigo's LTG-001 beat hydrocodone where suzetrigine couldn't. At a $1.4B market cap, LTGO is the pure-play bet. Here is why.
August 27, 2026Women's Health Stocks: ABCL Is the One Pure Play
AbCellera's ABCL635 is the only pure play in the non-hormonal menopause race and Natera's $2.9B diagnostics franchise is the durable base. The shelf ranked.
August 27, 20262026 Biotech Approval Scorecard: 10 Approvals, 2 Franchises
Ten drugs won FDA approval in 2026. Only Zenbexus and Fabhalta look like franchises, both mega-cap rounding errors. The pure plays remain unproven so far.
August 26, 2026Biotech IPO Reopening: $1.1B August Wave Ranked
August saw over $1.1B in biotech IPOs, from Phase 3-ready Apnimed to Phase 1 narrative plays. Here is the quality split and what it means for valuations.
August 26, 2026Liver Disease 2026: Rezdiffra $364M, 2 PBC Catalysts, Mirum
Madrigal's Rezdiffra posted $364M in Q2 sales, GSK and Zydus queue up PBC catalysts, and Bylvay's Phase 3 miss leaves biliary atresia to Mirum. Ranked.
August 26, 2026REGN Cemdisiran: gMG PDUFA vs Vyvgart's $4.2B
Cemdisiran, the first RNAi therapy for gMG, hits a November PDUFA with best-in-class data. The real beneficiary is Alnylam's platform, not Regeneron's stock.
August 26, 2026Roche Enspryng: Oct 15 TED PDUFA vs Tepezza
Enspryng's Oct 15 TED PDUFA is the first at-home challenger to Amgen's $1.9B Tepezza monopoly. Split Phase 3 data make this Amgen's loss, not Roche's win.
August 26, 2026IBD 2026: Merck TL1A Phase 3 Win, Spyre at $106
IBD is a $20B+ market, five mechanisms. Merck's tulisokibart won the first Phase 3 TL1A readout. Skyrizi and Tremfya own the revenue. The swing is a pure play.
August 25, 2026Nephrology 2026: Travere's $6B FSGS Monopoly vs Vertex IgAN
IgAN is crowded with three approvals and Vertex's Nov 30 PDUFA. FSGS remains a one-drug monopoly. Travere at $6B with 96% growth is the real kidney trade.
August 25, 2026PDUFA Dates September 2026: 11 FDA Decisions on the Calendar
September 2026 has 11 PDUFA dates: UX111 Sanfilippo gene therapy (Sept 19), zilganersen (Sept 22), and apitegromab (Sept 30) headline.
August 25, 2026Psychiatry: Cobenfy Muted, ML-007 Binary, MDD Graveyard
Cobenfy's launch is muted at $63M a quarter. MapLight ML-007 is a binary bet. Neumora's navacaprant went 0-for-3 and died. The winner is Axsome's Auvelity.
August 25, 2026PTGX at $154 Into the Rusfertide PDUFA: The Last 48 Hours of a 90% Bet
Rusfertide (MIMRYLO) won FDA approval Aug 28 for polycythemia vera, but PTGX at $10B had already priced it in. The label is what's left.
August 25, 2026Respiratory Biotech: Vertex CF Moat, IPF Graveyard, PAH Bet
The lung shelf: Vertex's $13B CF moat is unassailable, IPF's leader died and private Boehringer won, and PAH is a Merck side bet. One name is worth owning.
August 25, 2026Dermatology 2026 Catalysts: Barzolvolimab Leads 5 Trades
Five dermatology catalysts ranked: Celldex barzolvolimab Phase 3 CSU readout can double or halve a $3.17B stock; four more catalysts round out the shelf.
August 24, 2026Hematology 2026 Catalysts: Selinexor Leads 5 Trades
Five hematology catalysts ranked: Karyopharm selinexor in myelofibrosis is a $1.96 stock with a PDUFA trigger. Agios, Novo, and Immix round out the shelf.
August 24, 2026IgAN: Seven Drugs, Five Mechanisms, One Crowded Market
IgA nephropathy went from zero approved drugs to seven across five mechanisms in two years. Filspari and Vera's ORIGIN 3 readout are the two trades that matter.
August 23, 2026MIRM Zilurgisertib: Atebrioz Approved for FOP Sept 25
The FDA approved Mirum's Atebrioz (zilurgisertib) for FOP on September 25, one day early. This primer explains the PROGRESS data and the ALK2 inhibitor's place in a three-drug market.
August 23, 2026PTGX Rusfertide: $300M Royalty Math vs $10B PDUFA
Rusfertide's 76.9% vs 32.9% VERIFY win made approval near-certain — and PTGX at $9.9B already reflected it. Now it's the royalty math.
August 23, 2026REGN Pozelimab: VEXAS PDUFA Primer at $86B Market Cap
Pozelimab could be the first targeted therapy for VEXAS at its October 20 PDUFA. Approval looks near-certain, but it is a rounding error for an $86B company.
August 23, 2026Cardiometabolic 2026: 5 Heart-Disease Catalysts Ranked
While everyone chases obesity, the heart-disease and lipid pipeline is delivering approval-stage drugs. Here are 5 cardiometabolic catalysts ranked by risk.
August 22, 2026Immunology: 5 Autoimmune Catalysts Ranked by Risk-Reward
From J&J's first oral IL-23 pill to MoonLake's IL-17 nanobody, five autoimmune catalysts ranked by risk-reward with real trial data and live market caps.
August 22, 2026Ophthalmology 2026: 5 Retina Catalysts, Ranked by Risk
Wet AMD is a three-way fight, geographic atrophy is the next frontier, and gene therapy is entering retina. Here are 5 retina catalysts ranked by risk.
August 22, 2026Radiopharma: Pluvicto, Telix, and the $8B Isotope Moat
The Curium-Lantheus $8B deal marked radiopharma's graduation to core oncology. Here is how to rank Novartis's Pluvicto, Telix, and the isotope supply chain.
August 22, 2026ARGX Vyvgart Myositis Win: $12B Indication With a Catch
argenx's ALKIVIA Phase 3 hit in myositis added $12B of market cap, but the dermatomyositis miss means brepocitinib owns that half. IMNM is the real prize.
August 21, 2026Why CAR-T Cell Therapy Stocks Are Surging in 2026
CAR-T market: $8.95B in 2025 to a projected $19.25B by 2034. Three regulatory wins and manufacturing breakthroughs drive the move.
August 21, 2026 · OncologyEyePoint DURAVYU Lost 63%: How to Read a Post-Hoc Rescue
DURAVYU missed its LUGANO Phase 3 primary endpoint and pivoted to an ad hoc analysis excluding 9 of 211 patients. Here is why that is not the same as a win.
August 21, 2026LNTH TAUKLARIFY: Beats Tauvid, but $102.50 Buyout Caps It
TAUKLARIFY beat Tauvid on accuracy (AUC 0.93 vs 0.86), but Lantheus is locked into a $102.50 Curium buyout. The tau win is CVR upside, not a tradable catalyst.
August 21, 2026TEVA Ecopipam: First New Tourette Mechanism in 50 Years
Ecopipam won Priority Review on clean Phase 3 data and a first-in-class D1 mechanism. It will likely be approved, but a $400M franchise won't move a $43B stock.
August 21, 2026Alzheimer's Pipeline 2026: The Tau Bet After Two Failures
Alzheimer's has four competing hypotheses. Two failed in Phase 2/3, amyloid is plateauing, and tau just cleared its first real hurdle in Biogen's diranersen.
August 11, 2026Alzheimer's Pipeline 2026: Two Hypotheses Dead, One Plateauing, and the Tau Bet That Could Pay 3-to-1
Four competing Alzheimer's approaches: two failed, one is plateauing, and the tau hypothesis just cleared its first real hurdle in Phase 3.
August 11, 2026Biotech Insider Buying: When $3M Is a Trade Signal
Biotech insiders buy for one reason: they expect gains. A framework for separating the $3M cluster buy from the $10K PR stunt, using BRVE and ZBIO case studies.
August 11, 2026Cell Therapy Beyond CAR-T: CAR-NK, TIL, and the $400M Market
CAR-T is a $4B market. CAR-NK, TIL, and regenerative cell therapy are under $400M combined. Here is how each modality stacks up and which stocks lead.
August 11, 2026AMR Investing: The $100 Trillion Biotech Crisis
AMR will kill 10 million annually by 2050 and cost $100 trillion. The antibiotics market is broken, but that is exactly where the asymmetric returns live.
August 10, 2026Base Editing vs Prime Editing: Post-CRISPR Gene Therapy
Casgevy proved gene editing works. The double-strand break is a liability. Base editing and prime editing fix that. Five stocks ranked for the next wave.
August 10, 2026IRA Drug Pricing: Reshaping Biotech Valuations
The IRA is the biggest structural change to biotech economics since Hatch-Waxman. Here is which companies face the most risk and how to screen for IRA exposure.
August 10, 2026$236B Patent Cliff: Position for the Biotech M&A Supercycle
$236 billion in branded pharma revenue loses patent protection from 2026 to 2030. How to screen for biotech M&A targets before Big Pharma pays the premium.
August 9, 2026COGT Bezuclastinib NonAdvSM PDUFA: The Cleaner Catalyst
COGT faces two PDUFAs 30 days apart. GIST gets the attention but NonAdvSM has cleaner data, less competition, better risk-reward. The dual-catalyst playbook.
August 9, 2026December 2026 Biotech Catalysts: 4 PDUFAs, 2 Readouts Ranked
December closes the year with four PDUFAs and two Phase 3 readouts. We rank six catalysts by tradeable binary risk-reward, sorting ghosts from moneymakers.
August 9, 2026NUVB IBTROZI: $23M Revenue, 50-Month mDOR, $2.3B Question
IBTROZI hit $23.2M quarterly and leads ROS1 NSCLC. At $2.3B, safusidenib Phase 3 glioma data matters more than the January 2027 sNDA. Here is the setup.
August 9, 2026Q1 2027 Biotech Catalysts: 4 PDUFAs Ranked
Q1 2027 opens with four PDUFA dates: an sNDA label update, two first approvals, and one accelerated-to-full conversion. We rank each by tradeable risk-reward.
August 9, 2026BIIB Leqembi: $184M Q2, Donanemab Has 55% Share
Leqembi posted $184M in Q2 2026 sales, growing 15% YoY. But donanemab holds 55% market share. At $30.7B, BIIB prices in $1B+ Leqembi revenue. Here is why.
August 8, 2026MRNA mFlusiva: 27% Better Flu Efficacy, FDA Approved
FDA approved MRNA mFlusiva, first mRNA flu vaccine, 26.6% superior efficacy. Sanofi + GSK own the $6B+ market; it will not offset $782M losses at $23.6B.
August 8, 2026November 2026 Biotech Catalysts: Five PDUFAs Ranked
November 2026 drops five FDA decisions in 10 days: SVRA aPAP, BBIO LGMD2I, COGT GIST, GSK ALK, and a MRK ghost. Ranked by binary risk-reward. Here is the setup.
August 8, 2026Exelixis Q2: Cabometyx Tops $570M, Zanzalintinib NDA Is a December 3 Coin Flip
Exelixis beat Q2 with Cabometyx at $570.6M and a Dec 3 zanzalintinib CRC PDUFA — but the $12.93B market cap already prices in both.
August 7, 2026GSK Neladalkib: Nov 27 ALK NSCLC PDUFA Primer
GSK paid $10.6B for Nuvalent. Zidesamtinib delivered. Neladalkib heads to a Nov 27 PDUFA for TKI-pretreated ALK NSCLC. Data is real but GSK stock will not move.
August 7, 2026Mirum LIVMARLI EXPAND: After Bylvay's $2B Biliary Atresia Wipeout, the Field Is Mirum's to Lose
Bylvay failed its biliary atresia Phase 3, leaving Mirum's Q4 EXPAND readout as the only game in town — and $6.45B riding on the data.
August 6, 2026ARWR Plozasiran: $100M PRV Speeds sHTG Filing Behind Ionis
Arrowhead acquired a PRV to accelerate plozasiran's sHTG filing, but Ionis already has approval and $32M in 2026 TRYNGOLZA sales. Better data, later launch.
August 5, 2026BioMarin Vosoritide sNDA: Expanding Voxzogo to Children Under 5
BioMarin seeks to expand Voxzogo to children under 5 with achondroplasia. Feb 2027 PDUFA. BMRN at $59.99 with $11.7B market cap. Here is the risk-reward.
August 5, 2026 · Rare Disease · $BMRNEnanta EDP-978 Phase 3: A $387M Micro-Cap's One-Shot Urticaria Bet
Enanta (ENTA) at $13.34 is a $387M micro-cap betting everything on EDP-978 in chronic urticaria. Phase 3 data in Q4 2026. Here is the risk-reward.
August 5, 2026 · Immunology · $ENTAGLP-1 for Alzheimer's: A Good Bet That Did Not Pay Out
Semaglutide failed Alzheimer's Phase 3 EVOKE trials. Tirzepatide and retatrutide are next. The GLP-1 Alzheimer's hypothesis is dead as monotherapy. Here is what survives.
August 5, 2026 · Neuroscience · $NVOModerna and BioNTech: The mRNA Platform Is a Faster Way to Fail
Moderna spent $6B+ on R&D since 2020 with zero non-COVID approvals. BioNTech pivoted to oncology. The mRNA platform economics do not add up. Here is why.
August 5, 2026 · mRNA · $MRNANuvation Bio IBTROZI sNDA: Can the ROS1 Label Expansion Double Revenue?
Nuvation Bio (NUVB) at $6.40 seeks a first-line ROS1+ NSCLC label expansion for IBTROZI. Jan 4 PDUFA. Here is the pre-approval risk-reward analysis.
August 5, 2026 · Oncology · $NUVBADCT LOTIS-7 Full Data: $134M Market Cap, 89.8% ORR
ADCT LOTIS-7 full results Q4: 89.8% ORR in DLBCL at $134M market cap. LOTIS-5 hit but 13.2% Grade 5 safety clouds the picture. Value trap or opportunity?
August 4, 2026Multiple Myeloma: CAR-T First, Bispecifics at Relapse
CAR-T and bispecifics compete for the multiple myeloma market. CAR-T wins on efficacy, bispecifics on convenience. The sequencing data backs CAR-T first.
August 4, 2026RSV Vaccine Battle: GSK Leads, Moderna Bets, Pfizer Holds
Three RSV vaccines are fighting for a $10B market. GSK has the best data and won early lead. Moderna's stock depends on mRESVIA. Pfizer's is a rounding error.
August 4, 2026VRTX Povetacicept: Nov 30 PDUFA in Crowded IgAN Field
VRTX povetacicept: 52% proteinuria reduction, Nov 30 PDUFA in four-player IgAN market. Strong RAINIER data but a $300M drug does not move a $119B stock.
August 4, 2026BNTX at $90: $6.6B Oncology Pipeline, Founder Departures
BNTX trades near cash as founders depart and a Sobi operator takes over the oncology pivot. The pipeline is worth $6.6B to the market. Here is the setup.
August 3, 2026LLY Olomorasib: Second BTD Targets Pancreatic Cancer
LLY's next-gen KRAS G12C inhibitor earns Breakthrough Therapy in pancreatic cancer. At $1T market cap, the stock won't move on this. The pipeline does.
August 3, 2026RCKT RP-A501: $340M Danon Disease Gene Therapy Primer
RCKT RP-A501 resumed after a fatal 2025 setback. Three patients dosed safely at a lower dose. The binary question for investors: will efficacy survive the cut?
August 3, 2026AURA AU-011: $725M Choroidal Melanoma Phase 3 Primer
AURA's bel-sarotmecan Phase 3 CoMpass trial targets early choroidal melanoma, a rare eye cancer with zero approved drugs. Data due H2 2027. Here is the setup.
August 2, 2026HIV Cure: Three Strategies, Zero Approvals, 5 Years Out
Three HIV cure strategies: CRISPR, bNAbs, latency reversal. Gilead and ViiV have no incentive to hurry. The framework for evaluating every cure claim you read.
August 2, 2026October 2026 Biotech Catalysts: Two PDUFAs Ranked
October 2026 brings two FDA decisions — bepirovirsen in HBV and INO-3107 in RRP — after Merck withdrew the I-DXd SCLC BLA. Ranked by market cap and binary clarity.
August 2, 2026ACRS Bosakitug: $726M Anti-TSLP Eczema Phase 2 Primer
Aclaris at $726M market cap has a Phase 2 anti-TSLP antibody with 94% EASI-75 in a single-arm trial. The placebo-controlled readout in Q4 2026 is binary.
August 1, 2026BBOT BBO-11818: $648M pan-KRAS vs RVMD $40B
BridgeBio Oncology's pan-KRAS inhibitor enters Phase 1 with a confirmed PR in pancreatic cancer. At $648M vs RVMD's $40B, a cheap option on the KRAS race.
August 1, 2026Cancer Vaccines: Three Platforms, One Winner for MRNA
Cancer vaccines are three technologies at different stages. MRNA and BNTX lead mRNA neoantigen vaccines with 49% RFS reduction. Here is which platform wins.
August 1, 2026IMMX NXC-201 AL Amyloidosis: 95% CR at $592M
IMMX autologous BCMA CAR-T shows a 95% complete response rate in AL amyloidosis. At $592M market cap, the stock is a binary bet on the September data update.
August 1, 2026RGNX Sura-vec: $620M Gene Therapy for 2M Wet AMD Patients
REGENXBIO at $620M market cap is betting two Phase 3 trials can replace lifelong eye injections for 2M wet AMD patients. Q4 2026 topline data is binary.
August 1, 2026Sept 2026 Biotech Catalysts: Two Rare Disease PDUFAs
September brings two rare disease PDUFA dates at small-cap companies, plus a ghost catalyst from the GSK-Nuvalent deal. Here is the ranked trade setup.
August 1, 2026ABBV Q2: Skyrizi Overtakes Humira, $10.9B Apogee IL-13 Bet
AbbVie Q2 2026: Skyrizi hit $5.5B to surpass Humira. The $10.9B Apogee deal buys a pre-Phase 3 IL-13 drug with 3-month dosing. Fairly valued at $257 a share.
July 31, 2026CELC NCCN Win: 16 Days to Category 1, Stock Says Sell
REVTORPYK landed NCCN preferred Category 1 in 16 days, a signal that oncologists want this drug. At $4.3B with zero revenue, the science is ahead of the stock.
July 31, 2026IONS Bepirovirsen Oct 26 PDUFA: 19% HBV Functional Cure
Bepirovirsen delivers a 19% functional cure rate in hepatitis B. At $8.9B, IONS is the play, not GSK at $106B. PDUFA is October 26. Here is the full setup.
July 31, 2026KNSA KPL-387: Monthly IL-1 Shot Targets $1B Arcalyst
Kiniksa bets KPL-387 can replace weekly Arcalyst with monthly dosing for recurrent pericarditis. At 7x sales, the stock prices in perfection. Here is the setup.
July 31, 2026MRK I-DXd: BLA Withdrawn After FDA Flags Phase 2 Data
Merck and Daiichi Sankyo withdrew the ifinatamab deruxtecan BLA for SCLC after the FDA said Phase 2 data don't support accelerated approval. Oct 10 PDUFA off.
July 31, 2026 · Oncology · $MRKMRNA Q2: Norovirus Stalls, Aug 5 Flu PDUFA Is the Thesis
Moderna Q2 2026: $145M revenue, $782M loss. Norovirus vaccine missed Phase 3 interim. The August 5 flu PDUFA is now the entire thesis. Hold into the catalyst.
July 31, 2026NVS Del-brax FSHD Biomarker Endpoint Hit: $12B Avidity Bet
Novartis acquired Avidity for $12B. Del-brax just hit biomarker endpoints in FSHD with zero competition. But at $301B market cap, the BLA is a rounding error.
July 31, 2026RNA Therapeutics: Antisense vs RNAi at $8.9B vs $27.5B
Ionis and Alnylam are the two RNA platform leaders. After Alnylam's 29% guidance cut, the $18B market cap gap looks different. Five catalysts rank risk-reward.
July 31, 2026ROIV Brepocitinib: First DM Drug Priced Into $25B Platform
Roivant's brepocitinib could be the first approved dermatomyositis drug. At a $25B market cap, ROIV shareholders pay for the whole pipeline. Here is why.
July 31, 2026SNY Q2 Earnings: 3 Pipeline Cuts, Dupixent €5.2B
Sanofi beat earnings and raised guidance, but the stock fell 5.8% on €1B+ pipeline write-offs. At $43 and 1.9x sales, the discount is earned. The call: hold.
July 31, 2026BMY Q2 Earnings: 58% Growth, Priced In
BMY's Growth Portfolio hit 58% of revenue at +15% growth — but the $129B market cap already prices in the CELMoD pipeline and then some.
July 30, 2026Q4 2026 FDA Calendar: 5 PDUFAs That Move Stocks
Q4 2026 has 21 FDA PDUFA dates. Five are investable binary events. The rest are mega-cap noise or foreign-listed. Here is the ranked playbook for investors.
July 30, 2026GILD BIC/LEN: Cannibalizing the $14B Biktarvy Franchise
GILD's August 27 PDUFA for BIC/LEN is not a growth catalyst. It is Gilead competing with Biktarvy for the same patients. The stock will not move. Here is why.
July 30, 2026ID Biotech 2026: HBV Cure, HIV Shift, 5 Catalysts
Five infectious disease catalysts ranked. GILD BIC/LEN cannibalizes Biktarvy, GSK bepirovirsen could cure HBV, and Atea HCV ignored at $370M. Here is why.
July 30, 2026IONS Zilganersen PDUFA: Antisense Platform vs Alnylam
IONS at $8.9B with a Sept 22 PDUFA for zilganersen is not about Alexander disease revenue. It is about the antisense platform closing the gap with Alnylam.
July 30, 2026NBIX Q2 $959M: 3 Products Growing, 2027 Phase 3 Readouts
NBIX Q2 revenue jumped 39% to $959M with Ingrezza, Crenessity, and VYKAT XR all growing. The stock's fate hinges on two Phase 3 readouts in 2027. Hold for now.
July 30, 2026QURE AMT-130: 75% Huntington's Slowing at $2.78B
AMT-130 gene therapy showed 75% slowing of Huntington's at 36 months. BLA filing Q3 2026 under accelerated approval. At $2.78B, QURE is the purest HD play.
July 30, 2026Why 99% of Alzheimer's Drug Trials Fail
Alzheimer's trials fail 99% of the time. Five structural reasons, why Leqembi changed the bar but not the odds, and a framework for evaluating any catalyst.
July 30, 20267 Biotech Stocks With FDA Catalysts: Ranked by Risk-Reward
From Cogent's bezuclastinib to Savara's MOLBREEVI, seven biotech stocks with real PDUFA dates ranked by risk-reward. Two are explicit avoid calls. Here is why.
July 29, 2026August 2026 Biotech Catalysts: 4 PDUFAs, 2 Ghosts, Ranked
Replimune at $449M is the only small-cap binary event in August. Moderna, Gilead, and Jazz are mega-cap noise. Here is the ranked playbook for investors.
July 29, 2026Diagnostics Stocks Ranked: 5 Names Trading at 4x to 15x
Natera at $36B and Guardant at $19B are pricing in perfection. Lantheus at $6.7B is the value play. Here is the full diagnostics sector ranked for investors.
July 29, 2026FDA Approves JAZZ's Ziihera for First-Line HER2+ GEA — Full Analysis
Ziihera won front-line GEA approval on Aug 25 with median OS of 26.4 months — still the strongest Phase 3 win in HER2+ GEA history.
July 29, 2026SVRA MOLBREEVI PDUFA Moved to Nov 22: The $1.1B Binary Bet
SVRA at $5.28 has zero revenue, one BLA, and a PDUFA that just got pushed to November 22. The IMPALA-2 data is real. The question is whether the FDA agrees.
July 29, 2026BMY Mezigdomide PDUFA May 2027: 52% PFS Risk Reduction
BMS mezigdomide PDUFA May 13, 2027 after SUCCESSOR-2 showed 52% PFS risk reduction in myeloma; iberdomide (Zenbexus) approved Aug 13.
July 28, 2026CAR-T Stocks: 4 Catalysts, $465K Dose Moves Stocks 50%
CAR-T costs $465K per dose and cures blood cancers. Four 2026 catalysts from BMY, IMMX, ACET, and CRSP could each move stocks 30-50%. Here is the ranking.
July 28, 2026CRISPR Stocks: The Second Wave of Gene Editing
Five CRISPR stocks ranked by platform moat and pipeline reality. Casgevy is ramping, Intellia is the real bet, and Editas is a warning sign for investors.
July 28, 2026GLP-1 Stocks: Who Wins the $100B Obesity Market
Novo, Lilly, Roche, Viking, and Structure ranked by pipeline depth and valuation. Lilly is winning, Novo is chasing, and the oral pill war is the real fight.
July 28, 2026Neuroscience Biotech 2026: 5 Catalysts Ranked by Risk
From Biogen tau-targeting data to Takeda narcolepsy first-in-class, 5 neuroscience catalysts ranked by risk-reward using real trial data and market caps.
July 28, 2026Oncology Biotech 2026: 6 Catalysts, Only 2 Matter
Oncology has 6 PDUFA catalysts in 2026. Most are at mega-caps where approval is a rounding error. COGT at $6.9B and BBIO at $16.5B are the two that move.
July 28, 2026TAK Orzeyful Approved: First Orexin Agonist for $4B Narcolepsy Market
FDA approved Takeda's Orzeyful (oveporexton) on Aug 5, 2026 — the first orexin agonist. Phase 3 showed >80% cataplexy reduction and near-normal wakefulness.
July 28, 2026GOSS Seralutinib NDA: $0.20 Stock After Phase 3 Failure
GOSS plans to file an NDA for seralutinib despite missing its Phase 3 primary endpoint. At $0.20 and a $66M market cap, the market says the odds are near zero.
July 27, 2026mRNA Stocks: Moderna, BioNTech Platform Bets After COVID
Moderna and BioNTech face three catalysts in 2026 that could prove the mRNA platform extends beyond COVID. Here is the data behind the revaluation thesis.
July 27, 2026Rare Disease Stocks: 5 PDUFA Catalysts Could Move Stocks 30%
Six rare disease companies face PDUFA dates Aug to Dec 2026. Here is how I rank them by risk-reward, with the clinical data and market caps that matter.
July 27, 2026STOK Zorevunensen: $1.8B Bet on First Dravet Modifier
Stoke antisense drug upregulated NaV1.1 and cut seizures 85% in open-label data. The Phase 3 EMPEROR readout Q3 2027 is the binary catalyst for this $1.8B firm.
July 27, 2026ADC Stocks: Daiichi $10B Platform Is the Only Pure-Play
ADCs are oncology hottest theme. Pfizer, AbbVie, and Merck already paid up. Three 2026 catalysts remain and only one ticker offers pure exposure. Here is why.
July 26, 2026Gene Therapy Stocks: 5 Catalysts Worth $20B by Q1 2027
Gene therapy had a brutal 2023-2024. Five 2026 catalysts could prove the science works. RARE at $2.65B and RGNX at $623M are the contrarian plays. Here is why.
July 26, 2026Natera Signatera MCC Study: 90% Sensitivity, 13.5x Revenue
Signatera beat AMERK 90% to 55% in Merkel cell carcinoma. Natera's MRD moat is dominant, but at 13.5x forward revenue the stock leaves no margin for error.
July 26, 2026Arcus Casdatifan ARC-20: 15.1-Month PFS vs Belzutifan Moat
Arcus's casdatifan posted 15.1 months median PFS in late-line ccRCC. The data is solid, but Merck's Welireg generated $716M in 2025 and owns the HIF-2a class.
July 26, 2026Sanofi Venglustat NDA Accepted, PDUFA Nov 25 for GD3
SNY's venglustat hit p=0.007 in LEAP2MONO for GD3 neurological symptoms. At $43.35 with a Nov 25 PDUFA, the market is shrugging. Here is why that is right.
July 26, 2026BridgeBio BBP-418 PDUFA Nov 27: $16.5B Priced for Approval
BridgeBio BBP-418 has a Nov 27 PDUFA for LGMD2I with clean Phase 3 data. At $16.5B market cap, BBIO stock already prices in approval — a hold, not buy.
July 25, 2026Biogen Diranersen: First Tau Drug That Works, Phase 3 Risk
Biogen diranersen showed 50-65% tau reduction and 26% cognitive slowing in Phase 2 CELIA. But the primary endpoint missed. Phase 3 Alzheimer risk is real.
July 25, 2026GILD Anito-cel PDUFA: $7.8B BCMA CAR-T vs Carvykti
GILD December 23 PDUFA for anito-cel tests a 7.8B acquisition thesis against J&J Carvykti dominance in a 20B myeloma market. Fourth-mover risk looms large.
July 25, 2026GILD, MRK Once-Weekly HIV Pill: $162B Cannibalization Risk
ISL/LEN Phase 3 ISLEND data show non-inferiority for the first once-weekly HIV pill. GILD at $129 is pricing in lenacapavir dominance. The risk is Merck.
July 25, 2026JNJ Nipocalimab JASMINE: First FcRn Win in Lupus
JASMINE Phase 2: 53.6% SRI-4 at 52 weeks vs 39.7% placebo. Stelara is dying and argenx owns FcRn. Can nipocalimab carry JNJ immunology? JNJ is a hold.
July 25, 2026MRK Welireg + Lenvima RCC Approval: PFS Beat Over Cabozantinib
The FDA approved belzutifan plus lenvatinib for advanced RCC on Sept 24, 2026, 10 days early. Our earlier analysis of the LITESPARK-011 PFS beat over cabozantinib.
July 25, 2026NewAmsterdam Obicetrapib: CETP Clears EU, PREVAIL Bet
CHMP backed obicetrapib after 20 years of CETP failures. EU approval is real but the US path runs through PREVAIL. At $3.5B, NAMS prices in unearned CVOT win.
July 25, 2026Novartis Pluvicto: $2.6B Run Rate, Q3 mHSPC Catalyst
Pluvicto grew 43% in Q2 2026 to $651M. A Q3 mHSPC decision could quadruple the patient pool. At $155, Novartis is fairly valued with upside optionality.
July 25, 2026Ultragenyx UX111: A $2.65B Gene Therapy Bet on Sanfilippo
UX111 cuts CSF heparan sulfate 64% in Sanfilippo A. With a Sept 19 PDUFA, RARE at $2.65B prices in approval and a smooth launch. Here is why that is optimistic.
July 25, 2026SMMT at $10.9B: Ivonescimab PDUFA Is a Coin Flip
SMMT at $13.66 prices the Nov 14 ivonescimab PDUFA at 50-50. HARMONi missed its primary OS endpoint, but a 0.76 HR in Western patients keeps the flip alive.
July 25, 2026VRTX Casgevy 18 Months: 500 Patients, $43M Revenue
CRISPR's first approved therapy treated 500 patients and generated $43M in Q1 2026 revenue. Vertex prices in a steep ramp. Here is why the math is fragile.
July 25, 2026BridgeBio Encaleret NDA: $16B for a 5,000-Patient Market
BridgeBio encaleret NDA for ADH1 accepted with May 2027 PDUFA. CALIBRATE data is clean, but $16B valuation prices in perfect launch for 1-in-70,000 prevalence.
July 24, 2026Celcuity Revtorpyk Approved, Stock Down 18%: Piqray Problem
Celcuity won FDA approval for gedatolisib in PIK3CA wild-type breast cancer. The data is strong, stock fell 18%, and Novartis Piqray is the warning sign.
July 24, 2026DYN Z-Rostudirsen BLA: 10x SRPT Dystrophin, PDUFA 2027
Dyne BLA for z-rostudirsen in DMD is accepted with Priority Review. PDUFA January 21, 2027. Here is why the FORCE platform changes the exon-skipping math.
July 24, 2026Moderna Flu Vaccine: 9-0 AdComm Vote, Aug 5 PDUFA
mFLUSIVA's 26.6% efficacy edge over standard flu shots is real but modest. At $22.6B market cap with $1.3B quarterly losses, Moderna needs more than a vaccine.
July 24, 2026Nektar Rezpegaldesleukin Phase 3: $2.3B T-Reg Bet
Nektar rezpegaldesleukin enters Phase 3 in atopic dermatitis. Phase 2b hit every endpoint. At $2.3B and $69/share, NKTR prices in near-zero commercial success.
July 24, 2026Novo Semaglutide EVOKE Failed: GLP-1 Brain Hypothesis Dead
Novo semaglutide failed EVOKE in Alzheimer's with a 0.06-point CDR-SB miss. The GLP-1 brain hypothesis is dead. NVO at $48.77 is a hold on the GLP-1 franchise.
July 24, 2026Pfizer TALZENNA + XTANDI Cuts Prostate Cancer Risk 52%
Pfizer's TALZENNA plus XTANDI cut rPFS risk 52% in HRR-mutated prostate cancer. At $25 and a 7% yield, the stock is priced for decline. This sNDA matters.
July 24, 2026RVMD Daraxonrasib Cuts Pancreatic Cancer Death 60%
RASolute 302 showed a 60% death-risk reduction in pancreatic cancer. The data is real. At $40B market cap, RVMD leaves little room for error on NDA timeline.
July 24, 2026Vertex Crinetics $10B: 143x Revenue Multiple Deep Dive
Vertex paid $10B for Crinetics as sole bidder, valuing Palsonify at 143x revenue. Endocrine platform led by atumelnant may justify the premium. VRTX is a hold.
July 24, 2026VRTX $10B Crinetics: Sole Bidder, 130% Premium
VRTX spent $10B on Crinetics as sole bidder. Six others passed, one capped value at $6B. Here is why the 10% drop says the market is right to be skeptical.
July 24, 2026Moderna's mRNA-4157 Cancer Vaccine: Phase 2 Data Shows 44% RFS Reduction in Melanoma
Moderna's mRNA-4157 plus Keytruda cut melanoma recurrence 44%; a Nov 15 PDUFA could deliver the first approved mRNA cancer vaccine.
July 20, 2026 · mRNA · $MRNAAlnylam's Zilebesiran: RNAi for Hypertension Could Disrupt a $30B Market
Alnylam's zilebesiran showed sustained blood pressure reduction with twice-yearly dosing; the Phase 3 ZENITH outcomes trial is now starting.
July 17, 2026 · Rare Disease · $ALNYGilead's Lenacapavir: Twice-Yearly HIV PrEP Could Be a $5B Product
Gilead's lenacapavir (Yeztugo) won PrEP approval with twice-yearly dosing; Bixlenvo cleared Aug 27 and a weekly pill PDUFA lands Feb 2027.
July 16, 2026 · Infectious Disease · $GILD